CalciMedica Halts Phase II Kidney Injury Trial Following Safety Concerns, Stock Plummets 75%
核心洞察
CalciMedica terminated its Phase II KOURAGE trial evaluating Auxora in acute kidney injury patients after the independent data monitoring committee identified safety concerns requiring study design reevaluation.
The company's stock dropped over 75% following the announcement, with shares falling from $5.12 to $1.25 at market close, reflecting investor concerns about the program's future.
Despite the trial halt, CalciMedica reported no treatment-related deaths and no serious adverse events requiring expedited FDA reporting, with plans to review unblinded data to guide future development.
CalciMedica has terminated its Phase II KOURAGE trial evaluating Auxora (zegocractin) in patients with acute kidney injury (AKI) following a recommendation from the independent data monitoring committee, triggering a dramatic stock decline that wiped out over 75% of the company's market value.
The clinical-stage biopharmaceutical company announced the decision after the committee identified an unspecified safety concern during a prescheduled interim data review that "warrants reevaluation of the study design," particularly regarding patient enrollment criteria. The trial was evaluating Auxora in patients with Stage 2 or Stage 3 acute kidney injury with associated acute hypoxemic respiratory failure (AHRF), with data previously expected in the first half of 2026.
Market Response and Financial Impact
CalciMedica's stock experienced severe volatility following the announcement, dropping from $5.12 at market close on January 27 to an opening value of $0.85 on January 28, before settling at $1.25 at market close. The stock hit its 52-week low of 82 cents during the session and has declined approximately 66% over the past 12 months.
Trading volume surged to 23.27 million shares, dramatically exceeding the average volume of 84,063 shares. The stock is currently trading 83.5% below its 20-day simple moving average and 77% below its 100-day simple moving average, indicating significant technical weakness.
Safety Profile and Regulatory Communication
Despite the trial termination, CalciMedica emphasized that no deaths in the trial were assessed by investigators or the company as being related to Auxora or placebo. Additionally, no serious adverse events met the criteria for expedited reporting to the Food and Drug Administration.
Rachel Leheny, CEO of CalciMedica, stated, "To date, no treatment-related safety concern has been observed across more than 350 critically ill patients treated with Auxora in completed clinical trials, including the Phase 2b CARPO trial in acute pancreatitis (AP) and the Phase 2 CARDEA trial in severe COVID-19 pneumonia."
The company has notified the FDA about the trial discontinuation and is working with investigators to ensure all patients currently enrolled complete their full 90-day follow-up period.
Future Development Strategy
CalciMedica plans to conduct a comprehensive review of the unblinded clinical data, evaluating the impact of disease severity, baseline characteristics, and concomitant therapies to inform future clinical evaluations of Auxora in AKI. This analysis will guide the company's next development steps for the calcium release-activated calcium (CRAC) inhibitor in this indication.
The company remains optimistic about Auxora's potential in treating acute inflammatory illnesses and is focusing on finalizing the design of a pivotal trial in acute pancreatitis. Pending FDA feedback, the study design is expected to be complete by the first half of 2026.
Unmet Medical Need in AKI
According to recent research, AKI represents one of the most frequent complications associated with sepsis and cardiac surgery, affecting between 30-50% of patients in these settings. GlobalData estimates that approximately 199 in 100,000 people worldwide experience AKI, yet there are currently no approved targeted treatment options available for this patient population.
The standard of care for AKI currently revolves around addressing the underlying cause, managing fluid balance, and maintaining blood pressure levels. Limited development efforts exist for AKI prevention, including AstraZeneca's Alexion Pharmaceuticals subsidiary evaluating complement inhibitor Ultomiris (ravulizumab) in the Phase III ARTEMIS trial for reducing cardiac surgery-associated AKI risk in chronic kidney disease patients.